<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>&#x634;&#x631;&#x643;&#x629; &#x648;&#x627;&#x62F;&#x64A; &#x627;&#x644;&#x631;&#x64A;&#x627;&#x636;</provider_name><provider_url>https://rvc.com.sa/en/</provider_url><author_name>Hassan Khered</author_name><author_url>https://rvc.com.sa/en/author/hassan/</author_url><title>PROKARIUM GETS CLINICAL TRIAL APPROVAL - &#x634;&#x631;&#x643;&#x629; &#x648;&#x627;&#x62F;&#x64A; &#x627;&#x644;&#x631;&#x64A;&#x627;&#x636;</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="Cyn9FufYTV"&gt;&lt;a href="https://rvc.com.sa/en/prokarium-gets-clinical-trial-approval/"&gt;PROKARIUM GETS CLINICAL TRIAL APPROVAL&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://rvc.com.sa/en/prokarium-gets-clinical-trial-approval/embed/#?secret=Cyn9FufYTV" width="600" height="338" title="&#x201C;PROKARIUM GETS CLINICAL TRIAL APPROVAL&#x201D; &#x2014; &#x634;&#x631;&#x643;&#x629; &#x648;&#x627;&#x62F;&#x64A; &#x627;&#x644;&#x631;&#x64A;&#x627;&#x636;" data-secret="Cyn9FufYTV" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://rvc.com.sa/wp-content/uploads/2020/09/prokarium_.png</thumbnail_url><thumbnail_width>1798</thumbnail_width><thumbnail_height>985</thumbnail_height><description>Prokarium &#x201C;one of Riyadh Valley portfolio companies&#x201D;, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization (CTA) acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to run a first-in-human Phase I trial with Entervax&#x2122;, a bivalent vaccine against enteric fever. Prokarium anticipates...</description></oembed>
